Picture EBD Group Global Partnering Four Events One Price 650x80
Document › Details

ProteoNic Biotechnology B.V.. (2/5/19). "Press Release: ProteoNic Biotechnology Licenses Protein Production Technology to Eli Lilly and Company". Leiden.

Organisations Organisation ProteoNic Biotechnology B.V.
  Organisation 2 Eli Lilly & Co. Inc. (NYSE: LLY)
  Group Eli Lilly (Group)
Products Product 2G UNic™ expression technology
  Product 2 rPP [recombinant protein production]
Index term Index term Lilly–ProteoNic: rec protein production technology, 201902– license non-excl €na to use 2G UNic technology to boost rec protein production
Persons Person Pieper, Frank R. (ProteoNic 201109 CEO)
  Person 2 Posno, Mark (ProteoNic 201902 VP Business Development)

ProteoNic Biotechnology BV announces that it licensed its 2G UNic™ technology for boosting recombinant protein production to Eli Lilly and Company.

Under the agreement, Lilly gains non-exclusive commercial rights for application of the technology to the development of proprietary products. Financial details of the agreement were not disclosed.

ProteoNic’s mammalian protein expression technology is designed to improve recombinant cell line production levels across a range of host cells, selection systems and protein targets. It increases transcription and translation rates via the combined effect of novel genetic elements, which together exert a powerful positive effect on recombinant protein production levels as well as on stability of expression. ProteoNic’s 2G UNic™ can be combined with other technologies to improve their performance.

Frank Pieper, CEO of ProteoNic, states that 2G UNic™ technology can be instrumental in achieving the highest possible production levels and contribute to the economically viable production of both innovator and biosimilar products. ProteoNic will continue to work to reach maximum potential of the production of biologicals for current and future clients.

About ProteoNic Biotechnology BV

ProteoNic is a privately held company with offices in Leiden, the Netherlands and Boston, USA.

The company offers technology and services for the generation of cell lines with greatly improved biologics production characteristics, including production levels and stability. The company commercializes its proprietary 2G UNic™ technology through licensing and partnership arrangements. For more information, see

For more information please contact:

ProteoNic Biotechnology BV
Mark Posno
VP Business Development
T: +1 617 480 8016

Record changed: 2019-03-26


Picture [iito] Plain Stupid Simple 650x80px

More documents for ProteoNic Biotechnology B.V.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Network in German Capital Region 650x80px

» top